INDP
$1.96
Post-MarketAs of Mar 17, 8:00 PM UTC
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.96
Potential Upside
5%
Whystock Fair Value$2.06
Price
UndervaluedFair ValueOvervalued
Fundamentals
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination ther...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-317.98%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.61